Novo Nordisk is launching a cheaper authorised version of its blockbuster diabetes drug Ozempic in South Africa, intensifying its fight against unregulated compounded medicines, lower-cost generics and Eli Lilly’s fast-growing Mounjaro.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
